Hepion Pharmaceuticals, Inc. (HEPA) Balance Sheet

The consistent decline in total assets over the last ten quarters reflects a business model that is rapidly consuming its capital base without achieving commercial milestones. This trajectory suggests that the company is nearing a terminal state where the ability to sustain ongoing research activities is severely compromised.

While the current ratio appears superficially high due to low current liabilities, this metric is misleading given the absolute scarcity of liquid assets. Investors should monitor the company's ability to secure emergency funding, as the current cash position appears insufficient to support even basic administrative and R&D overhead for an extended period.

The persistent negative retained earnings highlight the high cost of clinical-stage development and the failure to generate offsetting value through successful product commercialization. This structural deficit suggests that any future equity issuance would likely result in significant dilution for existing shareholders, further complicating the company's capital structure.